Antibody-drug conjugates for H3K27M-mutant diffuse midline gliomas : prospects and challenges
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Therapeutic delivery - 12(2021), 8 vom: 04. Aug., Seite 553-557 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rechberger, Julian S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.08.2021 Date Revised 25.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/tde-2021-0045 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32831708X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32831708X | ||
| 003 | DE-627 | ||
| 005 | 20231225202705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2021-0045 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1094.xml |
| 035 | |a (DE-627)NLM32831708X | ||
| 035 | |a (NLM)34286602 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rechberger, Julian S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antibody-drug conjugates for H3K27M-mutant diffuse midline gliomas |b prospects and challenges |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.08.2021 | ||
| 500 | |a Date Revised 25.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a H3K27M | |
| 650 | 4 | |a antibody–drug conjugate | |
| 650 | 4 | |a convection-enhanced delivery | |
| 650 | 4 | |a diffuse intrinsic pontine glioma | |
| 650 | 4 | |a diffuse midline glioma | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a half-life | |
| 650 | 4 | |a targeted therapy | |
| 650 | 4 | |a theragnostic | |
| 650 | 4 | |a volume of distribution | |
| 650 | 7 | |a Immunoconjugates |2 NLM | |
| 700 | 1 | |a Power, Erica |e verfasserin |4 aut | |
| 700 | 1 | |a Millesi, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Daniels, David J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic delivery |d 2010 |g 12(2021), 8 vom: 04. Aug., Seite 553-557 |w (DE-627)NLM203937082 |x 2041-6008 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g number:8 |g day:04 |g month:08 |g pages:553-557 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/tde-2021-0045 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |e 8 |b 04 |c 08 |h 553-557 | ||